Leukogene Therapeutics, Inc

3:45 PM - 4:00 PM, Tuesday, June 4, 2019 ・ Theater 3
Leukogene Therapeutics, Inc. (LTI) is a start-up oncology drug discovery and development company out of the Medical University of South Carolina in Charleston, South Carolina. LTI is currently in the late stages of preclinical development for a new class of protein disulfide isomerase (PDI) inhibitor for the treatment of several solid and hematological cancers. LTI's lead molecules attack cancer through this novel mechanism, and have the added benefit of enhancing the effects of two other classes of targeted cancer therapy.
Ticker:
Not Provided.
Exchange:
Not Provided.
Company Type:
Company Website:
Company HQ State:
South Carolina
Company HQ Country:
United States
Year Founded:
2012
Main Therapeutic Focus:
Lead Product in Development:
LTI6426
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.
Speaker
photo
Chief Scientific Officer
Leukogene Therapeutics, Inc.